about
sameAs
Nanoporous CREG-eluting stent attenuates in-stent neointimal formation in porcine coronary arteriesImmune-mediated vascular injury and dysfunction in transplant arteriosclerosisOral rapamycin attenuates inflammation and enhances stability of atherosclerotic plaques in rabbits independent of serum lipid levels.Rapamycin inhibits re-endothelialization after percutaneous coronary intervention by impeding the proliferation and migration of endothelial cells and inducing apoptosis of endothelial progenitor cells.Modulating the functional contributions of c-Myc to the human endothelial cell cyclic strain responseEvaluation of the impact of the cancer therapy everolimus on the central nervous system in miceTherapeutic potential of active stent coating.Role of oral rapamycin to prevent restenosis in patients with de novo lesions undergoing coronary stenting: results of the Argentina single centre study (ORAR trial).Drug-eluting stents: a mechanical and pharmacologic approach to coronary artery disease.Mammalian target of rapamycin (mTOR) inhibition in chronic lymphocytic B-cell leukemia: a new therapeutic option.Everolimus-eluting coronary stentsEverolimus: an immunosuppressive agent in transplantation.XIENCE V everolimus-eluting coronary stent system: a novel second generation drug-eluting stent.Drug-induced immunomodulation to affect the development and progression of atherosclerosis: a new opportunity?Telomerase Inhibition by Everolimus Suppresses Smooth Muscle Cell Proliferation and Neointima Formation Through Epigenetic Gene SilencingXience V everolimus-eluting coronary stent.Emerging drugs for coronary restenosis: the role of systemic oral agents the in stent era.Low-dose oral sirolimus reduces atherogenesis, vascular inflammation and modulates plaque composition in mice lacking the LDL receptorMetal allergy to everolimus-eluting cobalt chromium stents confirmed by positive skin testing as a cause of recurrent multivessel in-stent restenosis.Predicting in vivo efficacy of potential restenosis therapies by cell culture studies: species-dependent susceptibility of vascular smooth muscle cells.Antimonocyte chemoattractant protein-1 gene therapy reduces experimental in-stent restenosis in hypercholesterolemic rabbits and monkeys.Two-year safety and effectiveness of the platinum chromium everolimus-eluting stent for the treatment of small vessels and longer lesions.Rapamycin modulates the eNOS vs. shear stress relationship.Synergistic suppression of rat neointimal hyperplasia by rapamycin and imatinib mesylate: implications for the prevention of accelerated arteriosclerosis.Revisiting the role of durable polymers in cardiovascular devices.Effect of Self-Expanding Carotid Stents on Plaque Thickness and Vessel Diameter.Oral mycophenolate mofetil prevents in-stent intimal hyperplasia without edge effect.Modulation of Immunologic Response by Preventive Everolimus Application in a Rat CPB Model.Requirements for quantitative analysis of intimal reaction in arteries treated with intraluminal stents.PLATINUM China: a prospective, randomized investigation of the platinum chromium everolimus-eluting stent in de novo coronary artery lesions.Neoatherosclerosis and Late Thrombosis After Percutaneous Coronary Intervention: Translational Cardiology and Comparative Medicine from Bench to Bedside.
P2860
Q27329486-F57D648B-D2D1-4AD3-AC2F-D3423F36C9E3Q28084366-2EBA968F-1438-443D-8266-34341797A7B4Q30482901-DD747838-0FDD-4ADA-B040-74E774C77C47Q33776274-076A2657-6602-465D-8A14-FF3BA70C4AA1Q33792177-10ADD2AA-CCA4-4CC2-B823-37FD7AE6E359Q34600979-A1580BDD-4708-42BC-8B5A-446895F4D140Q35117070-D83C093B-680B-4264-BADB-52D6F4B767DBQ35584915-9E6C5CF0-F89E-4301-81C0-BA076F607710Q35945466-45B904F3-3359-4DDF-93EF-C7B06BD5770AQ35994885-706B7EE2-57C0-4D61-B80B-D59A4F7BC394Q36160432-93DBEC2F-2FCF-43B1-B785-EA1F63EA02CAQ36521866-F486F47E-911D-498F-9672-CDCFE82AA614Q36691665-4A7038F4-1976-42CF-9C9B-D04046864D73Q36752124-07B2BDD7-7749-4F15-AA19-89586A52D3B1Q36830744-CA89B4F6-AE26-4AD6-8F66-13EF7BFFE23AQ37472070-37A95520-AEA5-4086-B3D2-CDDDAF1AB862Q37588002-3FA6D866-46CD-4A8E-A0D9-1CFF5DC11745Q41424778-8943FD27-959B-4D78-9F82-C039CFA16640Q42701667-E07C81B8-0A48-4739-BC22-CCCCA0794AA3Q43250028-B6AC5EAE-DFD1-48E6-A9E0-2145FB50A545Q45875756-4FF53FB6-CB82-43DF-9340-7C6A1B8BD2E3Q46405787-FF66A40B-931C-4CDC-9D9F-5DA4ED7EFEADQ46851063-986C4194-363C-4C32-A5E3-B3F373E77895Q46893100-C9102C92-C95C-4B6C-BAEE-6C49DD40518EQ49486591-C974593F-F214-4FFF-ADBC-DF30B1B59059Q50758529-A5E96A96-B406-4E1F-9E7B-E95EE747D482Q51112819-90DED627-8A82-4967-9DDD-BB2C0C085F9BQ51606652-C5A192B2-3328-4568-ACD8-49368A9522C2Q51722355-86ED9EC6-FF68-435B-BB75-49CA63BA08A6Q53326510-0A62B78B-A9B3-419E-B54D-ECF75A613D0DQ54763757-296E22B7-0E5C-4915-9564-5D984E2F9F89
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Oral everolimus inhibits in-stent neointimal growth
@ast
Oral everolimus inhibits in-stent neointimal growth
@en
Oral everolimus inhibits in-stent neointimal growth
@nl
type
label
Oral everolimus inhibits in-stent neointimal growth
@ast
Oral everolimus inhibits in-stent neointimal growth
@en
Oral everolimus inhibits in-stent neointimal growth
@nl
prefLabel
Oral everolimus inhibits in-stent neointimal growth
@ast
Oral everolimus inhibits in-stent neointimal growth
@en
Oral everolimus inhibits in-stent neointimal growth
@nl
P2093
P1433
P1476
Oral everolimus inhibits in-stent neointimal growth
@en
P2093
Andrew Farb
Eduardo Acampado
Frank D Kolodgie
Margaret Forney Prescott
Michael John
Renu Virmani
P304
P356
10.1161/01.CIR.0000033973.06059.04
P407
P577
2002-10-29T00:00:00Z